Proteomics International Says Blood Test Shows Diagnostic Accuracy for All Stages of Esophageal Cancer, Shares Rise 7%

MT Newswires Live

Sep 19, 2025

Proteomics International Laboratories (ASX:PIQ) said results from a 350-person study for its blood test for esophageal adenocarcinoma, PromarkerEso, showed that the test has excellent discrimination for all stages of the cancer, as well as high levels of sensitivity, specificity, positive and negative predictive values for all stages, according to a Friday Australian bourse filing.

The results of the study demonstrated that the increasing severity of disease is significantly correlated with increasing PromarkerEso test scores.

The test also showed acceptable performance for diagnosing the pre-malignant condition Barrett's Esophagus with high-grade dysplasia.

The results of the study will be presented at the ISDE World Congress for Esophageal Diseases in Brisbane on Friday, and PromarkerEso will be formally launched at the conference. The test is available across Australia to patients through a telehealth consultation and physician referral.

Its shares rose 7% in recent trading on Friday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2568233388"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2568233388\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2568233388?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-19 10:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2568233388","market":"nz","top_or_hot":-1,"title":"Proteomics International Says Blood Test Shows Diagnostic Accuracy for All Stages of Esophageal Cancer, Shares Rise 7%","media":"MT Newswires Live","content":"<html><body><p> Proteomics International Laboratories (ASX:PIQ) said results from a 350-person study for its blood test for esophageal adenocarcinoma, PromarkerEso, showed that the test has excellent discrimination for all stages of the cancer, as well as high levels of sensitivity, specificity, positive and negative predictive values for all stages, according to a Friday Australian bourse filing.</p><p>The results of the study demonstrated that the increasing severity of disease is significantly correlated with increasing PromarkerEso test scores.</p><p>The test also showed acceptable performance for diagnosing the pre-malignant condition Barrett's Esophagus with high-grade dysplasia.</p><p>The results of the study will be presented at the ISDE World Congress for Esophageal Diseases in Brisbane on Friday, and PromarkerEso will be formally launched at the conference. The test is available across Australia to patients through a telehealth consultation and physician referral.</p><p>Its shares rose 7% in recent trading on Friday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Proteomics International Says Blood Test Shows Diagnostic Accuracy for All Stages of Esophageal Cancer, Shares Rise 7%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nProteomics International Says Blood Test Shows Diagnostic Accuracy for All Stages of Esophageal Cancer, Shares Rise 7%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-09-19 10:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Proteomics International Laboratories (ASX:PIQ) said results from a 350-person study for its blood test for esophageal adenocarcinoma, PromarkerEso, showed that the test has excellent discrimination for all stages of the cancer, as well as high levels of sensitivity, specificity, positive and negative predictive values for all stages, according to a Friday Australian bourse filing.</p><p>The results of the study demonstrated that the increasing severity of disease is significantly correlated with increasing PromarkerEso test scores.</p><p>The test also showed acceptable performance for diagnosing the pre-malignant condition Barrett's Esophagus with high-grade dysplasia.</p><p>The results of the study will be presented at the ISDE World Congress for Esophageal Diseases in Brisbane on Friday, and PromarkerEso will be formally launched at the conference. The test is available across Australia to patients through a telehealth consultation and physician referral.</p><p>Its shares rose 7% in recent trading on Friday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"XJO.AU","symbol_name":"标普/澳交所 200指数","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2568233388","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2568233388","pubTimestamp":1758248054,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Proteomics International Laboratories  said results from a 350-person study for its blood test for esophageal adenocarcinoma, PromarkerEso, showed that the test has excellent discrimination for all stages of the cancer, as well as high levels of sensitivity, specificity, positive and negative predictive values for all stages, according to a Friday Australian bourse filing.The results of the study demonstrated that the increasing severity of disease is significantly correlated with increasing PromarkerEso test scores.The test also showed acceptable performance for diagnosing the pre-malignant condition Barrett's Esophagus with high-grade dysplasia.The results of the study will be presented at the ISDE World Congress for Esophageal Diseases in Brisbane on Friday, and PromarkerEso will be formally launched at the conference. The test is available across Australia to patients through a telehealth consultation and physician referral.Its shares rose 7% in recent trading on Friday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"XJO.AU":"标普/澳交所 200指数","BK7048":"生命科学工具和服务","XKO.AU":"标普/澳交所 300指数","BK7508":"医药生物股","XAO.AU":"标普/澳交所 普通股指数","PIQ.AU":"PROTEOMICS INTERNATIONAL LAB"},"translate_title":"Proteomics International称血液测试显示食道癌所有阶段的诊断准确性，股价上涨7%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XKO.AU":0.71,"PIQ.AU":1,"XAO.AU":0.71,"XJO.AU":0.71},"content_text":"Proteomics International Laboratories (ASX:PIQ) said results from a 350-person study for its blood test for esophageal adenocarcinoma, PromarkerEso, showed that the test has excellent discrimination for all stages of the cancer, as well as high levels of sensitivity, specificity, positive and negative predictive values for all stages, according to a Friday Australian bourse filing.The results of the study demonstrated that the increasing severity of disease is significantly correlated with increasing PromarkerEso test scores.The test also showed acceptable performance for diagnosing the pre-malignant condition Barrett's Esophagus with high-grade dysplasia.The results of the study will be presented at the ISDE World Congress for Esophageal Diseases in Brisbane on Friday, and PromarkerEso will be formally launched at the conference. The test is available across Australia to patients through a telehealth consultation and physician referral.Its shares rose 7% in recent trading on Friday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}